274 related articles for article (PubMed ID: 32772754)
21. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Chang VY; Wang JJ
Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
[TBL] [Abstract][Full Text] [Related]
22. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
Armenian SH
Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
[TBL] [Abstract][Full Text] [Related]
23. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
[TBL] [Abstract][Full Text] [Related]
24. GSTM1 null variant associated with anthracycline-related cancer in pediatric cancer.
Rassekh SR
Cancer; 2020 Sep; 126(17):3926-3928. PubMed ID: 32413168
[No Abstract] [Full Text] [Related]
25. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
26. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W
Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697
[TBL] [Abstract][Full Text] [Related]
27. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
Chen JJ; Wu PT; Middlekauff HR; Nguyen KL
Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H213-H222. PubMed ID: 27923793
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
[TBL] [Abstract][Full Text] [Related]
29. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
[TBL] [Abstract][Full Text] [Related]
30. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.
Berkman AM; Hildebrandt MAT; Landstrom AP
Clin Genet; 2021 Aug; 100(2):132-143. PubMed ID: 33871046
[TBL] [Abstract][Full Text] [Related]
31. Predictors of anthracycline-induced cardiotoxicity in a retro-prolective cohort of children surviving cancer.
Rivas-Ruiz R; Ureña-Wong K; Castelán-Martínez OD; Betanzos-Cabrera Y; Lazo-Cárdenas C; Ramírez-Portillo C; López-Aguilar E
Gac Med Mex; 2020; 156(3):217-223. PubMed ID: 32539021
[TBL] [Abstract][Full Text] [Related]
32. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
Wu V
J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
[TBL] [Abstract][Full Text] [Related]
33. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
34. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
35. Anthracycline associated cardiotoxicity in survivors of childhood cancer.
Lipshultz SE; Alvarez JA; Scully RE
Heart; 2008 Apr; 94(4):525-33. PubMed ID: 18347383
[No Abstract] [Full Text] [Related]
36. Intrauterine Growth Retardation is a Risk Factor for Anthracycline Toxicity.
Eroglu N; Yoldas T; Bilgin B; Yesil S; Fettah A; Sahin G
Pediatr Hematol Oncol; 2021 Aug; 38(5):497-503. PubMed ID: 33715575
[TBL] [Abstract][Full Text] [Related]
37. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
[TBL] [Abstract][Full Text] [Related]
38. An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Dionne F; Aminkeng F; Bhavsar AP; Groeneweg G; Smith A; Visscher H; Rassekh SR; Ross C; Carleton B
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29271558
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity in anthracycline therapy: Prevention strategies.
Cruz M; Duarte-Rodrigues J; Campelo M
Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
[TBL] [Abstract][Full Text] [Related]
40. Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.
Ding Y; Du K; Niu YJ; Wang Y; Xu X
Oxid Med Cell Longev; 2022; 2022():5818612. PubMed ID: 35965684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
